Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer (NCT04787744)
Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for OligoRecurrenT Prostate Cancer (VA STARPORT)
🩺 Plain-English Summary (8th-Grade Level)
This is a prospective, open-label, multi-center seamless phase II to phase III randomized clinical trial designed to compare SST with or without PET-directed local therapy in improving the castration-resistant prostate cancer-free survival (CRPC-free survival) for Veterans with oligometastatic prostate cancer. Oligometastasis will be defined as 1-10 sites of metastatic disease based on the clinical determination of the LSI which incorporates all imaging, clinical, and pathologic data available.
Who can join: Review the eligibility criteria below.
Location: VA Long Beach Healthcare System, Long Beach, CA — Long Beach, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (20 Sites)
- VA Long Beach Healthcare System, Long Beach, CA — Long Beach, California
- VA Greater Los Angeles Healthcare System, West Los Angeles, CA — West Los Angeles, California
- Washington DC VA Medical Center, Washington, DC — Washington D.C., District of Columbia
- Bay Pines VA Healthcare System, Pay Pines, FL — Bay Pines, Florida
- Edward Hines Jr. VA Hospital, Hines, IL — Hines, Illinois
- Richard L. Roudebush VA Medical Center, Indianapolis, IN — Indianapolis, Indiana
- Baltimore VA Medical Center VA Maryland Health Care System, Baltimore, MD — Baltimore, Maryland
- VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA — Boston, Massachusetts
- VA Ann Arbor Healthcare System, Ann Arbor, MI — Ann Arbor, Michigan
- Minneapolis VA Health Care System, Minneapolis, MN — Minneapolis, Minnesota
- Kansas City VA Medical Center, Kansas City, MO — Kansas City, Missouri
- East Orange Campus of the VA New Jersey Health Care System, East Orange, NJ — East Orange, New Jersey
- VA NY Harbor Healthcare System, New York, NY — New York, New York
- Durham VA Medical Center, Durham, NC — Durham, North Carolina
- Louis Stokes VA Medical Center, Cleveland, OH — Cleveland, Ohio
- Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA — Philadelphia, Pennsylvania
- Michael E. DeBakey VA Medical Center, Houston, TX — Houston, Texas
- Hunter Holmes McGuire VA Medical Center, Richmond, VA — Richmond, Virginia
- William S. Middleton Memorial Veterans Hospital, Madison, WI — Madison, Wisconsin
- Clement J. Zablocki VA Medical Center, Milwaukee, WI — Milwaukee, Wisconsin
📞 Contact the Study Coordinator
Phone: (708) 202-8387
Email: Abhishek.Solanki@va.gov
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Prostate Cancer
- A Study of Apalutamide (JNJ-56021927, ARN-509) Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With mHSPC — Homewood, Alabama
- A Study in Which Non-metastatic Castration-resistant Prostate Cancer (nmCRPC) Patients for Whom a Decision to Treat With Darolutamide Has Been Made Before Enrollment Are Observed and Certain Outcomes Are Described — Homewood, Alabama
- Stereotactic Ablative Radiation Therapy for Prostate Cancer — Charleston, South Carolina
- A Study of Stereotactic Body Radiation Therapy (SBRT) Without Androgen Deprivation Therapy (ADT) in People With Unfavorable Intermediate-Risk Prostate Cancer — Basking Ridge, New Jersey
- A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer — Phoenix, Arizona
- Neoadjuvant Enoblituzumab (MGA271) in Men With Localized Intermediate and High-Risk Prostate Cancer — Baltimore, Maryland
Explore by condition: All Prostate Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.